STOK vs ACAD

For growth investors, Stoke Therapeutics, Inc.

(STOK) is the stronger pick with 404. 5% revenue growth year-over-year, versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 4x trailing P/E (48. 5x forward), making it the more compelling value choice. Analysts rate Stoke Therapeutics, Inc. (STOK) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Stoke Therapeutics, Inc.

(STOK) delivered a total return of +6. 0%, compared to +2. 5% for ACADIA Pharmaceuticals Inc. (ACAD). Over 10 years, the gap is even starker: STOK returned +30. 2% versus ACAD's -22. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stoke Therapeutics, Inc.

(STOK) is the lower-risk stock at 0. 91β versus ACADIA Pharmaceuticals Inc. 's 1. 26β — meaning ACAD is approximately 38% more volatile than STOK relative to the S&P 500.

By revenue growth (latest reported year), Stoke Therapeutics, Inc.

(STOK) is pulling ahead at 404. 5% versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). On earnings-per-share growth, the picture is similar: Stoke Therapeutics, Inc. grew EPS 92. 7% year-over-year, compared to 68. 4% for ACADIA Pharmaceuticals Inc.. Over a 3-year CAGR, STOK leads at 145. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -3. 7% for Stoke Therapeutics, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -11. 2% for STOK. At the gross margin level — before operating expenses — STOK leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ACAD: 61.

9% to $34. 78.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Stoke Therapeutics, Inc.

(STOK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 91)). Both have compounded well over 10 years (STOK: +30. 2%, ACAD: -22. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: STOK is a small-cap high-growth stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.